Key clinical point: Treatment with belimumab on top of standard systemic lupus erythematosus therapy safely improved renal function during 2 years on treatment compared with patients who did not receive the drug.
Major finding: After 2 years, the primary endpoint renal response occurred in 43% who received belimumab and 32% of control patients .
Study details: BLISS-LN, a multicenter, randomized trial with 446 evaluable patients.
Disclosures: BLISS-LN was sponsored by GlaxoSmithKline, the company that markets belimumab (Benlysta). Dr. Furie is a consultant to and has received research funding from GlaxoSmithKline, and several of the study’s coauthors are employees of the company.
Furie RA et al. Ann Rheum Dis. 2020 Jun;79[suppl 1]:103, Abstract OP0164.